Please use this identifier to cite or link to this item:
metadata.artigo.dc.title: Technological monitoring study based on invention patents of omeprazole and derivatives with pharmaceutical applications
metadata.artigo.dc.creator: Oliveira, Leandra Guimarães de
Carestiato, Tatiana
Mothé, Cheila Gonçalves
Souza, Raimundo Vicente de
metadata.artigo.dc.subject: Omeprazole
Technological foresight
Pharmaceutical patents
metadata.artigo.dc.publisher: Universidad Alberto Hurtado (UAH), Facultad de Economía y Negocios Oct-2010
metadata.artigo.dc.identifier.citation: OLIVEIRA, L. G. de et al. Technological monitoring study based on invention patents of omeprazole and derivatives with pharmaceutical applications. Journal of Technology Management & Innovation, Santiago, v. 5, n. 3, p. 110-119, out. 2010. DOI: 10.4067/S0718-27242010000300008.
metadata.artigo.dc.description.abstract: The current study intends to present the relevance of omeprazole, esomeprazole, rabeprazole, pantoprazole and lansoprazole by means of the technological foresight study, through invention patent documents from Brazilian applicants as indicators of innovation. The European database of patents (Espacenet), Word Patent Index (DERWENT) and the Brazilian Patent Base of INPI were used, combining keywords and International Patent Classifications. The major applicants, countries of publication and claims categories were mapped. The 212 patent requests collected are mainly distributed in Chemistry, Pharmacy and Pharmacology areas. The results obtained revealed that the US was the main country with studies directed to this technological area (59 patent applications) and the major applicant was the company Astrazeneca AB. Therefore, we can understand that this is a promising technology that may reflect in an increase of R&D activities and patent applications in this area.
metadata.artigo.dc.language: en_US
Appears in Collections:DAG - Artigos publicados em periódicos

This item is licensed under a Creative Commons License Creative Commons